The authors would like to draw the reader's attention to the errors in the following article:
Takada K, Sugita S, Murase K, Kikuchi T, Oomori G, Ito R, Hayasaka N, Miyanishi K, Iyama S, Ikeda H, Kobune M, Emori M, Kato J, Hasegawa T. Exceptionally rapid response to pembrolizumab in a SMARCA4‐deficient thoracic sarcoma overexpressing PD‐L1: A case report. Thoracic Cancer 2019; 11: 2312–15. https://doi.org/10.1111/1759-7714.13215.
On pages 2313 and 2314, ‘SMARCA2 (INI1)’ should read as ‘SMARCB1 (INI1)’ in the Case report section and figure 2 caption.
The authors apologize for the errors and any inconvenience these may have caused.